Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials

Fig. 1

Percent PSA transition from baseline to month 13. a Mean percent PSA change in JPN-201, (n). b Percent PSA change for each patient in JPN-201; green, PSA ≤ −30 % (30 %-decline); blue, −30 % < PSA < 25 % (non-decline); red, PSA ≥ 25 % (25 %-elevation) according to PSA change at week 4. c Mean percent PSA change in JPN-202, (n). d Percent PSA change for each patient in JPN-202; green, PSA ≤ −30 % (30 %-decline); blue, −30 % < PSA < 25 % (non-decline); red, 25 % ≥ PSA (25 %-elevation) according to PSA change at week 4. Data are expressed as mean ± 95 % CI. Note: PSA changes of ≥ 300 % and those after month 13 are not shown

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us